Forgot your password?

Forgot your username?

Portola Pharmaceuticals Biotech Specialty Pharma

270 E. Grand Avenue, Suite 22
South San Franciso, CA 94080 USA
Click for website
Research Sector Biotech Specialty Pharma
Summary Description Anticoagulant and Antiplatelet Medications to Avert Thrombosis

Click here for Financial Data Keywordschronic cardiovascular disease, betrixaban, PRT060128, Factor Xa inhibitor, ADP receptor, elinogrel, atrial fibrillation, antithrombotic, thrombosis


Portola Pharmaceuticals, Inc. specializes in developing therapeutics for the treatment and prevention of severe cardiovascular diseases. The company's earlier-stage programs are focused on the discove......view more

Products / Services

Portola's portfolio includes two lead Phase II compounds designed to prevent thrombosis; betrixaban is an oral Factor Xa inhibitor anticoagulant and elinogrel (PRT060128) is an antagonist to the P2Y12......view more

Technology / Differentiation

Betrixaban is an oral anticoagulant that directly inhibits Factor Xa, a validated target in the blood coagulation pathway. Elinogrel is the only direct acting and reversible P2Y12 ADP receptor antagon...view more

Market / Customers

Portola's product candidates address needs in the hospital, specialty, and chronic care markets and are indicated for use in various acute and chronic cardiovascular diseases, which account for 57 per......view more


Portola announced that it entered a worldwide license agreement with Novartis for the development and commercialization of elinogrel in February 2009. The company expects to receive a $75 million upfr...view more